Skip to main content


Latest News

Cancer, neurodegenerative disease and medicines safety feature in new IMI Call for proposals

Brussels, Belgium, 30 November 2017 – Today, the Innovative Medicines Initiative (IMI) is launching a new Call for proposals covering diabetes, antimicrobial resistance, neurodegenerative diseases, cancer, and medicines safety during pregnancy and breastfeeding, to name just a few. The total budget of the Call is EUR 223 million, around half of which comes from the EU’s Horizon 2020 programme, and half of which comes from EFPIA companies and IMI Associated Partners.


Webinars on IMI2 - Call 13


New brochure: Carrying the torch for medical innovation


First batches of ULTRA-DD patient-based assay data released - ahead of publication




IMI projects delivering high quality 

The sheer volume and high quality of publications coming out of IMI projects is highlighted in the latest analysis of IMI publications carried out by Clarivate Analytics (formerly Thomson Reuters).

IMI has been monitoring and analysing the papers coming out of its projects since 2012, and the number of publications is increasing year-on–year. In 2016 alone, IMI projects produced 796 publications, bringing the total number of publications produced by IMI projects to over 2 600. 






New IMI video

Carrying the torch for medical innovation

Diseases keep changing, and infections we treated for decades can once again kill. By bringing together researchers from the public and private sectors, we are working to speed up medicines development and turn knowledge into treatments. Watch our #CarryTheTorch video and share it!